The most common adverse events of any grade were nausea ( @ -LSB- @ % -RSB- of @ patients in the gefitinib group and @ -LSB- @ % -RSB- of @ patients in the placebo group ) and decreased appetite ( @ -LSB- @ % -RSB- and @ -LSB- @ % -RSB- ) .